Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

the acute treatment of agitation in schizophrenic or bipolar disorder patients, has completed both of the planned Phase 3 clinical trials. The Company has completed its end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), which is intended for the acute treatment of migraine headache, and it has advanced AZ-104 (Staccato loxapine) to Phase 2 testing. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. In addition, AZ-002 (Staccato alprazolam) has completed a Phase 2a proof-of-concept clinical trial for the acute treatment of panic attacks -- an indication the Company is not planning to pursue -- and is being assessed for other possible indications and renewed clinical development. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential, efficacy and safety of AZ-004. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Re
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 RadiologyAuction will have their first auction ... product demonstrations at the end of the auction on ... Kodak and Fuji Cr,s, Agfa and Sony, printers and ... event. Various imaging equipment will be available at later ... After years of buying and selling imaging equipment, the ...
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... announces that a new market research report ... Byetta (Type 2 Diabetes) – Analysis ... http://www.reportlinker.com/p0657148/Byetta-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Byetta (Type ... 2020 Summary ...
... Reportlinker.com announces that a new market research ... Aesthetic Lasers and Energy Devices - ... http://www.reportlinker.com/p0575304/Aesthetic-Lasers-and-Energy-Devices---Global-Market-Briefing-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Beauty_Salon_and_Services Aesthetic Lasers ... 2017 Summary ...
Cached Medicine Technology:Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 5Byetta (Type 2 Diabetes) - Analysis and Forecasts to 2020 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 2Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 4Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 5Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 7Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 8Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 9
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Jones Arena in Charlottesville, VA. McCartney is one ... music business and this beloved performer continues to roll along ... member of two legendary groups: Wings and The Beatles, has ... since 2013 on the “Out There” tour and has continually ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New York, NY (PRWEB) May 04, 2015 ... Mother Hale Learning Center from Hale House. The Mother ... by offering high-quality, affordable Early Childhood Education. Sheltering Arms ... families will continue to be served by the center. ... serves 45 children ages six weeks to five years, ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... In response to the proposed ... Force (USPSTF), Strategic Radiology® (SR®) fully aligns itself ... and Gynecologists (ACOG), the American College Of Surgeons, ... Society (ACS), American College of Radiology (ACR), and ... regular screening mammography for women beginning at age ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5
... to a recent Florida State University study, hospitals can ... IT// for all hospital operations. ,According to ... Manatee Memorial and Lakewood Ranch Medical Centre, have already ... few years. He said that, the hospitals are yet ...
... beyond the youth segments as far as their clientele is concerned. ... in Japan has taken to "Brain Train" concept like a duck ... million of its "Brain Training for Adults" game, which was released ... were not interested in video games ... But we did not ...
... are that is the medicine metformin is taken once daily ... ,In the words of co-author Dr. Bret Berner, "With ... 2000 mg a day. The new formulation, which goes by ... higher doses.” ,Dr. Bret Berner is chief scientific ...
... MIT scientists have developed a technology that uses the ... which function as in very thin lithium-ion batteries.// ... Yet-Ming Chiang have by simply manipulating a few genes ... the viruses grow and self-assemble into a functional electronic ...
... people who escaped from the horrifying attacks on the World ... depression, anxiety and other psychological problems even three years after ... Centers for Disease Control and Prevention said that the people ... breathing problems of a severe nature. "The trauma of being ...
... with the proposal of the Ministry of Health to hike ... ,"A committee has been set up to review fees ... private medical sector. This includes the licensing and renewal of ... of the medical or health establishments as well," said Dr ...
Cached Medicine News:Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products: